Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes

Drug Metabolism and Disposition

Volumn 30, Issue 7, 2002, Pages 853-858

  Hijazi, Youssef ^a   Boulieu, Roselyne ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; ENZYME INHIBITOR; KETAMINE; KETOCONAZOLE; NIFEDIPINE; ORPHENADRINE; CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ISOENZYME; N DEMETHYLASE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; HALF LIFE TIME; KINETICS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMAN; ISOENZYMES; KETAMINE; KINETICS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; HUMANS;

EID: 0035987904     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.7.853     Document Type: Article

References (33)

1. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
2. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fuvoxamine drug interaction in man
3. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high purity reversed phase sorbent
4. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
5. Antipyrine metabolism in cultured rat hepatocytes
6. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity and role in procarcinogen activation
7. Further characterization of the expression in liver and catalytic activity of CYP2B6
8. Comparison of levels of several human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples
9. Selective inhibitors of cytochromes P450
10. Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples
11. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
12. The nonmedical use of ketamine, part two: A review of problem use and dependance
13. Pharmacokinetics of ketamine and two metabolites in the dog
14. Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism
15. Metabolism of ketamine stereoisomers by human liver microsomes
16. Evaluation of Omeprazole and Lansoprazole as inhibitors of cytochrome P450 isoforms
17. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation
18. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
19. Characterization of CYP2C 19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide. S-mephenytoin and omeprazole hydroxylation
20. Tissue distribution of ketamine in a mixed drug fatality
21. Urine concentrations of ketamine and norketamine following illegal consumption
22. Ketamine on demand for postoperative analgesia
23. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for enzyme-specific complexation of cytochrome P-450 and inhibition kinetics
24. Use of in vitro human metabolism studies in drug development. An industrial perspective
25. Interaction of cyclophosphamide and ketamine in vivo
26. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
27. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
28. Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine
29. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratio of accessory proteins as sources of discrepancies between the approaches
30. Ketamine-its pharmacology and therapeutic uses
31. Biotransformation of ketamine, (Z)-6-hydroxyketamine and (E)-6-hydroxyketamine by rat, rabbit and human liver microsomal preparations
32. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450-reductase system and studies with apo-cytochrome b5
33. Involvement of CYP2B6 in the N-demethylation of ketamine in human liver microsomes